EP
CPRX

Essential Partners’s Catalyst Pharmaceutical CPRX Stock Holding History

Essential Partners’s Portfolio CPRX Stock Details CPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$619 Buy
25
+2
+9% +$48 ﹤0.01% 2372
2025
Q4 		$537 Buy
23
+7
+44% +$156 ﹤0.01% 2216
2025
Q3 		$315 Sell
16
-487
-97% -$10K ﹤0.01% 2311
2025
Q2 		$10.9K Buy
+503
New +$11.9K ﹤0.01% 822

Other funds holding CPRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Essential Partners's CPRX Position: Q1 2026 in Review

Essential Partners increased its Catalyst Pharmaceutical (CPRX) stake by 8.7% in Q1 2026, buying an estimated $48 and bringing the position to 25 shares worth $619. The position accounts for ﹤0.01% of the portfolio, ranked #2372.

Essential Partners first reported a position in CPRX in Q2 2025 and has held it in 4 quarters since. The position peaked at $10.9K in Q2 2025. 380 funds tracked by Wall St. Rank hold CPRX as of Q1 2026.

  • Essential Partners held 25 shares of Catalyst Pharmaceutical worth $619 as of Q1 2026.
  • Essential Partners bought 2 Catalyst Pharmaceutical shares in Q1 2026, an estimated $48.
  • Catalyst Pharmaceutical made up ﹤0.01% of Essential Partners's portfolio in Q1 2026, its #2372 holding.
  • Essential Partners first reported a position in Catalyst Pharmaceutical in Q2 2025 and has held it in 4 quarters since.
  • Essential Partners's Catalyst Pharmaceutical position peaked at $10.9K in Q2 2025.
  • 380 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q1 2026.

Based on Essential Partners's 13F filing for Q1 2026, filed 21 May 2026.